NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
17/12/2024
Voltar para busca
Dado oficial do USPTO
E&S HEALTHCARE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
E&S HEALTHCARE
ST13
US500000090031610Classe
5, 10
Pedido
90031610
Registro
7602896
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
58
Atualização mais recente
17/12/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 10
Data de depósito
01/07/2020
Data de registro
17/12/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
17/12/2024
Última transação
17/12/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
03
Localização do titular
Daejeon, KR
Examinador
PERKINS, ELLEN
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
E&S Healthcare Co., Ltd.
Representantes
Max Vern AMSTER, ROTHSTEIN & EBENSTEIN LLP
Classificação técnica
Classes Nice
Classe 5Classe 10
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Diagnostic reagents for medical use for immune disease; diagnostic reagents for medical use; medical diagnostic reagents; diagnostic reagents for medical or veterinary purposes; immunoassay diagnostic reagents for medical purposes; biological reagents for medical purposesbiological reagents for medical diagnostic purposes; reagents for medical diagnostic purposes for the analysis of body fluids; reagent paper for medical purposes; medicated lozenges; chemical reagents for medical purposes; diagnostic reagents for medicinal use; clinical medical reagents; clinical diagnostic reagents in the nature of clinical medical reagents
Classe 10
Medical device for detecting cancer; medical devicein vitro diagnostic medical device for detecting breast cancer by Thioredoxin 1(Trx1) expression level; medical device for breast cancer detection for medical usenamely breast cancer diagnostic kit comprised of serum collection empty enzyme-linked immunosorbent assay (ELISA) plate for medical purposesanti-Thioredoxin 1(Trx 1) antibody coated 96-well plateTrx 1 calibrator and anti-Trx 1 detection antibody; medical diagnostic apparatus for detecting cancer and testing for viruses; apparatus for blood testing for medical use; medical device and apparatus in the field of clinical diagnosisa breast cancer diagnostic kit comprised of serum collection empty enzyme-linked immunosorbent assay (ELISA) plate for medical purposesantiThioredoxin 1(Trx 1) antibody coated 96-well plateTrx 1 calibrator and anti-Trx 1 detection antibody; testing instruments for medical diagnostic purposesa breast cancer diagnostic kit comprised of serum collection empty enzyme-linked immunosorbent assay (ELISA) plate for medical purposesanti-Thioredoxin 1(Trx 1) antibody coated 96-well plateTrx 1 calibrator and anti-Trx 1 detection antibody; tools for medical diagnosticsa breast cancer diagnostic kit comprised of serum collection empty enzyme-linked immunosorbent assay (ELISA) plate for medical purposesanti-Thioredoxin 1(Trx 1) antibody coated 96-well plateTrx 1 calibrator and anti-Trx 1 detection antibody; medical diagnostic apparatusanalytical apparatus for medical purposes and blood pressure measuring apparatus; blood analysis apparatus for diagnosis.
Publicações
Histórico de despachos e eventos da marca no USPTO.
58 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
17/12/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/09/2024
PUBO
PUBLISHED FOR OPPOSITION
10/09/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
21/08/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/08/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
08/08/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/08/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
08/08/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/08/2024
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
08/05/2024
GNFR
FINAL REFUSAL E-MAILED
08/05/2024
CNFR
FINAL REFUSAL WRITTEN
08/05/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
27/03/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
27/03/2024
NREV
NOTICE OF REVIVAL - E-MAILED
26/03/2024
PGRR
PETITION GRANTED - RESPONSE RECEIVED
26/03/2024
APET
ASSIGNED TO PETITION STAFF
26/03/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
22/02/2024
PROA
TEAS PETITION TO REVIVE RECEIVED
22/02/2024
MAB2
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
23/01/2024
ABN2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
23/01/2024
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
26/09/2023
GNSI
INQUIRY TO SUSPENSION E-MAILED
26/09/2023
CNSI
SUSPENSION INQUIRY WRITTEN
26/09/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
10/03/2023
GNSL
LETTER OF SUSPENSION E-MAILED
10/03/2023
CNSL
SUSPENSION LETTER WRITTEN
10/03/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/03/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/03/2023
ALIE
ASSIGNED TO LIE
09/03/2023
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
02/03/2023
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
05/12/2022
GNSI
INQUIRY TO SUSPENSION E-MAILED
05/12/2022
CNSI
SUSPENSION INQUIRY WRITTEN
05/12/2022
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
10/05/2022
GNSL
LETTER OF SUSPENSION E-MAILED
10/05/2022
CNSL
SUSPENSION LETTER WRITTEN
10/05/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/04/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/04/2022
ALIE
ASSIGNED TO LIE
18/04/2022
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
14/04/2022
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
14/10/2021
GNSI
INQUIRY TO SUSPENSION E-MAILED
14/10/2021
CNSI
SUSPENSION INQUIRY WRITTEN
14/10/2021
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
13/10/2021
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
26/03/2021
GNSL
LETTER OF SUSPENSION E-MAILED
26/03/2021
CNSL
SUSPENSION LETTER WRITTEN
26/03/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/03/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/03/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/03/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
13/10/2020
GNRT
NON-FINAL ACTION E-MAILED
13/10/2020
CNRT
NON-FINAL ACTION WRITTEN
13/10/2020
DOCK
ASSIGNED TO EXAMINER
06/10/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
29/07/2020
NWAP
NEW APPLICATION ENTERED
04/07/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace E&S HEALTHCARE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.